We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

55 hedge funds and large institutions have $448M invested in Ventyx Biosciences in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

20% more funds holding

Funds holding: 4655 (+9)

2.67% more ownership

Funds ownership: 62.84%65.51% (+2.7%)

28% less capital invested

Capital invested by funds: $619M → $448M (-$171M)

41% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 17

Holders
55
Holders Change
+9
Holders Change %
+19.57%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
14
Increased
10
Reduced
17
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VP
1
venBio Partners
California
$68M
TP
2
Third Point
New York
$58.5M
Citadel Advisors
3
Citadel Advisors
Florida
$51.4M +$279K +20,882 +0.5%
LGM
4
Logos Global Management
California
$34.1M +$9.22M +690,000 +38%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$28.2M -$437K -32,678 -2%
VC
6
Vivo Capital
California
$26.1M +$1.74M +130,451 +7%
RI
7
RTW Investments
New York
$21.1M
Wellington Management Group
8
Wellington Management Group
Massachusetts
$20.3M -$4.35M -325,557 -18%
EC
9
EcoR1 Capital
California
$17.6M
O
10
OrbiMed
New York
$17.5M
FCM
11
Farallon Capital Management
California
$15.1M
QUSVM
12
Qiming U.S. Ventures Management
Washington
$12.4M
Fidelity Investments
13
Fidelity Investments
Massachusetts
$11.1M +$45K +3,367 +0.4%
CAM
14
Cormorant Asset Management
Massachusetts
$10.7M
DCM
15
Driehaus Capital Management
Illinois
$8.69M -$164K -12,306 -2%
BlackRock
16
BlackRock
New York
$6.67M -$45K -3,366 -0.7%
Vanguard Group
17
Vanguard Group
Pennsylvania
$6.47M -$1.22K -91 -0%
American Century Companies
18
American Century Companies
Missouri
$5.33M +$1.59K +119 +0%
GPP
19
Great Point Partners
Connecticut
$4.56M +$4.49M +336,334 New
MCMC
20
Matrix Capital Management Company
New Hampshire
$4.55M +$4.48M +335,000 New
Barclays
21
Barclays
United Kingdom
$3.92M +$3.86M +289,040 New
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$3.07M +$3.02M +226,300 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$2.65M +$108K +8,113 +4%
State Street
24
State Street
Massachusetts
$2.32M +$903K +67,590 +65%
WP
25
Woodline Partners
California
$1.63M

VTYX Hedge Fund Activity: Q1 2022 in Review

55 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q1 2022, worth a combined $448M — down 28% from $619M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new VTYX positions and 5 closed out — a net gain of 9 holders — while 10 added to existing stakes and 17 trimmed.

The largest buyer was Logos Global Management, adding an estimated $9.22M. The largest seller was Wellington Management Group, cutting an estimated $4.35M.

  • 55 institutional investors held Ventyx Biosciences (VTYX) as of Q1 2022, up from 46 in Q4 2021.
  • Funds reported $448M of Ventyx Biosciences stock for Q1 2022, down 28% quarter-over-quarter.
  • 14 funds opened new Ventyx Biosciences positions in Q1 2022 and 5 closed out, a net change of +9 holders.
  • The largest Ventyx Biosciences buyer in Q1 2022 was Logos Global Management, an estimated $9.22M added.
  • The largest Ventyx Biosciences seller in Q1 2022 was Wellington Management Group, an estimated $4.35M sold.

Based on aggregated 13F filings for Q1 2022.